Results 81 to 90 of about 38,144 (289)

Delta-opioid receptor endocytosis in spinal cord after dermenkephalin activation

BMC Neuroscience, 2000
Background The delta(δ)-opioid receptors belong to the G protein-coupled receptors and in vitro studies have shown that δ-opioid receptors undergo an internalization process in response to agonist stimulation.
Gastard Myriam
doaj   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well‐documented intoxication cases and basic pharmacological data

Addiction, EarlyView.
Abstract Background and aims While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity.
Michaela J. Sommer, Katharina Elisabeth Grafinger, Maren Hermanns‐Clausen, Volker Auwärter   +3 more
wiley   +1 more source

Patients’ perceptions of self-administered dosing to opioid agonist treatment and other changes during the COVID-19 pandemic: a qualitative study [PDF]

, 2023
Gemma Scott, Sophie Turner, Natalie Lowry, Annette Hodge, Waniya Ashraf, Katie McClean, Mike Kelleher, Luke Mitcheson, John Marsden   +8 more
openalex   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder

Addictive Behaviors Reports, 2018
Introduction: People with chronic opioid use disorder often present to treatment with individual and structural vulnerabilities and remain at risk of reporting adverse health outcomes.
Heather Palis, Kirsten Marchand, Mohammad Karamouzian, Scott MacDonald, Scott Harrison, Daphne Guh, Kurt Lock, Suzanne Brissette, Aslam H. Anis, Michael Krausz, David C. Marsh, Martin T. Schechter, Eugenia Oviedo-Joekes   +12 more
doaj   +1 more source

Impact of Changes to the Delivery of Opioid Agonist Treatment, Introduced During the COVID-19 Pandemic, On Treatment Access and Dropout in Ireland: An Interrupted Time Series Analysis

, 2022
Louise Durand, Fiona Boland, Norma Harnedy, Íde Delargy, Mike Scully, Margaret Bourke, William Ebbitt, María Otero Vázquez, Eamon Keenan, Gráinne Cousins   +9 more
openalex   +1 more source

Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities [PDF]

, 2023
Zoe Friedmann, H.J. Kinkel, C. Kühner, Andreas Zsolnai, Inge Mick, Annette Binder   +5 more
openalex   +1 more source

The association of methadone use with physical function and frailty among persons who inject drugs

Addiction, EarlyView.
Abstract Background and Aims Persons who inject drugs (PWID) experience a high burden of early‐onset frailty, primarily due to multifactorial causes such as infections (human immunodeficiency virus [HIV], hepatitis C virus [HCV]), substance use, and polypharmacy.
Grace L. Kulik, Hsing‐Yu Hsu, Jacqueline Rudolph, Yutong Jiang, Kristine M. Erlandson, Damani A. Piggott, Shruti Mehta, Jeremy D. Walston, Gregory Kirk, Todd T. Brown, Jing Sun   +10 more
wiley   +1 more source

Fentanyl assisted treatment: a possible role in the opioid overdose epidemic?

Substance Abuse Treatment, Prevention, and Policy, 2019
Background The current opioid overdose epidemic affecting communities across North America is increasingly driven by illicitly manufactured fentanyl and its related analogues.
Geoff Bardwell, Evan Wood, Rupinder Brar
doaj   +1 more source